BACKGROUND We aimed to build a modified systemic inflammatory score(mSIS) based on preoperative albumin, fibrinogen, lactate dehydrogenase, and neutrophil-lymphocyte ratio in patients with high-grade glioma. MATERIAL AND METHODS Data of 318 patients with high-grade gliomas were retrospectively analyzed. The SIS was developed and its associations with clinicopathological features and overall survival (OS) were evaluated. RESULTS The mSIS consisted of serum albumin, fibrinogen, lactate dehydrogenase and neutrophil-lymphocyte ratio. A high mSIS was significantly associated with age(p < 0.001), sex(p = 0.048), lymphocyte-monocyte ratio (LMR)(p = 0.025), C-reactive protein(p < 0.001), tumor grade(p = 0.006) and served as an independent prognostic factor of reduced overall survival and progression-free survival (PFS). Subgroup analysis showed that the mSIS could significantly stratify patient prognosis in different tumor grades and adjuvant therapies. CONCLUSIONS mSIS may predict survival and disease regression in high-grade glioma patients undergoing surgery. Management of HGG patients may need consideration of host inflammatory status.

中文翻译：

---

改良全身炎症评分对新诊断高级别胶质瘤患者的预后价值

背景我们旨在建立基于术前白蛋白、纤维蛋白原、乳酸脱氢酶和中性粒细胞-淋巴细胞比率的改良全身炎症评分（mSIS），用于高级别胶质瘤患者。材料与方法回顾性分析318例高级别胶质瘤患者的资料。开发了 SIS 并评估了其与临床病理特征和总生存期 (OS) 的关联。结果 mSIS 由血清白蛋白、纤维蛋白原、乳酸脱氢酶和中性粒细胞-淋巴细胞比率组成。高 mSIS 与年龄（p < 0.001）、性别（p = 0.048）、淋巴细胞-单核细胞比率（LMR）（p = 0.025）、C 反应蛋白（p < 0.001）、肿瘤分级（p = 0.006）显着相关) 并作为降低总生存期和无进展生存期 (PFS) 的独立预后因素。亚组分析表明，mSIS 可以显着地对不同肿瘤分级和辅助治疗的患者预后进行分层。结论 mSIS 可以预测接受手术的高级别胶质瘤患者的生存率和疾病消退。HGG 患者的管理可能需要考虑宿主炎症状态。